Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RT102 + RT105
- Development stage
- Preclinical
- Lead developer
- Royaltechmed
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
RT102 + RT105 is a preclinical-stage combination bacterial-based therapy developed by Royaltechmed. Utilizing the company's proprietary bacteria platform, the candidate is designed to treat various solid malignancies, including non-small cell lung cancer (NSCLC), liver cancer, rectal cancer, and prostate cancer. Bacterial therapies typically leverage the natural ability of certain bacteria to colonize the hypoxic regions of tumors, where they can be engineered to express therapeutic proteins, induce local inflammation, or recruit immune cells to the tumor microenvironment. This program represents a novel approach within the microbial therapy space, aiming to harness live biotherapeutics for oncological applications.
- Other names
- RT102~RT105
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on RT102 + RT105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RT102 + RT105.